Hence, C3G may play a relevant role in physiological and/or pathological processes involving platelets, such as cancer or cardiovascular diseases, and may represent a new biomarker and/or therapeutic target in platelets. This evidence concerns the gene RAPGEF1 and cardiovascular disorder.